TY  - JOUR
AU  - Argüelles-Arias, Federico
AU  - Fernández Álvarez, Paula
AU  - Castro Laria, Luisa
AU  - Maldonado Pérez, Belén
AU  - Belvis Jiménez, María
AU  - Merino-Bohórquez, Vicente
AU  - Caunedo Álvarez, Ángel
AU  - Calleja Hernández, Miguel Ángel
PY  - 2022
DO  - 10.17235/reed.2021.8320/2021
SN  - 1130-0108
UR  - http://hdl.handle.net/10668/21716
T2  - Revista espanola de enfermedades digestivas
AB  - A new subcutaneous formulation of the infliximab biosimilar CT-P13 has recently been developed for the treatment of inflammatory bowel disease (IBD), providing response rates similar to intravenous treatment. The use of this new formulation was...
LA  - en
KW  - Biosimilar Pharmaceuticals
KW  - COVID-19
KW  - Drug Substitution
KW  - Gastrointestinal Agents
KW  - Humans
KW  - Inflammatory Bowel Diseases
KW  - Infliximab
KW  - Pandemics
KW  - Prospective Studies
KW  - Retrospective Studies
KW  - SARS-CoV-2
KW  - Treatment Outcome
TI  - Switch to subcutaneous infliximab during the SARS-CoV-2 pandemic: preliminary results.
TY  - research article
VL  - 114
ER  -